explore -WSS

explore

author：entertainment 2025-10-01 12:35:27 - browse：62

Two boxes of Ozempic stack on each other, while one lean on the stack tilted — health coverage from STAT — SEBASTIEN BOZON/AFP via Getty Images

Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs approved to treat this population.

Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the study parameters, this implies that over three years, 39 people would need to be treated to prevent one death from any cause, according to new results presented Friday at a meeting of the European Renal Association and published in the New England Journal of Medicine.

Ozempic also lowered the risk of major heart complications — including cardiovascular-related death, heart attack, or stroke — by 18%, driven primarily by the reduced rate of heart-linked death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： The inclusion problem at the heart of rehabilitation research

Wikipedia

focus

WSS

The 10 drugs up first for Medicare price negotiation

The 10 drugs up first for Medicare price negotiation

Printout prescription drug information shouldn’t go digital

Medicare bonuses could stop drug shortages under Senate plan

A new House health package & hospitals’ new site

Microsoft launches AI tool for clinical documentation through Epic

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

23andMe had bad news about my health. I wish a person had delivered it

Medicaid rebukes states for mistakenly disenrolling children

Novavax promises a turnaround & Lilly roils the obesity market

NIH nominee Bertagnolli will get October confirmation hearing

Cancer drug shortages should be causing more outrage

How to protect patients from sexual assault

United colonoscopy coverage change 'may cost lives,' doctors say

ALS advocates say criticism of new drugs misses bigger picture

Drug repurposing or repositioning? The language matters

Head of FDA's diagnostics center, who led through Covid, retires

knowledge

Ethical issues complicate the benefits of medical crowdfunding

There's an unseen cost to disruptive road

Flu vaccine reformulation won't be easy, manufacturers warn

Head of FDA's diagnostics center, who led through Covid, retires

What American doctors can learn from their Israeli counterparts

A rare thyroid diagnosis led to unexpected, all

Wikipedia

focus

focus

Wikipedia